1. Sandler KA, Shaverdian N, Cook RR, Kishan AU, King CR, Yang I, Steinberg ML, Lee P.“Treatment trends for patients with brain metastases: Does practice reflect the data?” Cancer. 2017 Feb 8. doi: 10.1002/cncr.30607.
  2. Shaverdian N, Verruttipong D, Wang PC, Kishan AU, Demanes DJ, McCloskey S, Kupelian P, Steinberg ML, King CR. “Exploring Value From the Patient’s Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer.” Int J Radiat Oncol Biol Phys. 2017 Mar 1;97(3):516-525.
  3. Kishan AU, Kupelian PA, Steinberg ML, King CR. “Urinary toxicity after stereotactic body radiotherapy: The boy who cried wolf?” Cancer. 2017 Feb 1;123(3):531-532.
  4. Mesko S, Sandler K, Cohen J, Konecny G, Steinberg M, Kamrava M. “Clinical Outcomes for Stereotactic Ablative Radiotherapy in Oligometastatic and Oligoprogressive Gynecological Malignancies.” Int J Gynecol Cancer. 2017 Feb;27(2):403-408.
  5. Wang C, King CR, Kamrava M, Iwamoto KS, Chen AM, Low D, Kupelian PA, Steinberg ML.“Pattern of solid and hematopoietic second malignancy after local therapy for prostate cancer.” Radiother Oncol. 2017 Feb 7. pii: S0167-8140(17)30031-2.
  6. Hegde JV, Margolis DJ, Wang PC, Reiter RE, Huang J, Steinberg ML, Kamrava M.“Establishing the distribution of satellite lesions in intermediate- and high-risk prostate cancer: implications for focused radiotherapy.” Prostate Cancer Prostatic Dis. 2017 Jan 31. doi: 10.1038/pcan.2016.75.
  7. Shaverdian N, Yang Y, Hu P, Hart S, Sheng K, Lamb J, Cao M, Agazaryan N, Thomas D, Steinberg M, Low DA, Lee P. “Feasibility evaluation of diffusion-weighted imaging using an integrated MRI-radiotherapy system for response assessment to neoadjuvant therapy in rectal cancer.” Br J Radiol. 2017 Jan 12:20160739. doi: 10.1259/bjr.20160739.
  8. Rwigema JC, Lamiman K, Reznik RS, Lee NJH, Olch A, Wong KK. “Palliative radiation therapy for superior vena cava syndrome in metastatic Wilms tumor using 10XFFF and 3D surface imaging to avoid anesthesia in a pediatric patient—a teaching case” Advances in Radiation Oncology. [Article in Press].
  9. Wang C, Kamrava M, King C, Steinberg ML. “Racial Disparity in Prostate Cancer-Specific Mortality for High-Risk Prostate Cancer: A Population-Based Study.” Cureus. 2017 Jan 6;9(1):e961.


  1. Sandler KA, Veruttipong D, Agopian VG, Finn RS, Hong JC, Kaldas FM, Sadeghi S, Busuttil RW, Lee P. “Stereotactic body radiotherapy (SBRT) for locally advanced extrahepatic and intrahepatic cholangiocarcinoma.” Advances in Radiation Oncology. 2016 October-December. 1 (4):236-243.
  2. Shaverdian N, Veruttipong D, Wang J, Kupelian P, Steinberg M, Lee P. “Location Matters: Stage I Non-Small-cell Carcinomas of the Lower Lobes Treated With Stereotactic Body Radiation Therapy Are Associated With Poor Outcomes.” Clin Lung Cancer. 2016 Oct 28. pii: S1525-7304(16)30225-X.
  3. Kishan AU, Lee P. “Radiation Therapy for Stage I Nonoperable or Medically Inoperable Lung Cancer.” Semin Respir Crit Care Med. 2016 Oct;37(5):716-726.
  4. Raghavan G, Kishan AU, Cao M, Chen AM. “Anatomic and dosimetric changes in patients with head and neck cancer treated with an integrated MRI- tri-60Co teletherapy device.” Br J Radiol. 2016 Sep 21:20160624.
  5. Shaverdian N, Wang J, Levin-Epstein R, Schaue D, Kupelian P, Lee P, Yang I, Kaprealian T. “Pro-inflammatory State Portends Poor Outcomes with Stereotactic Radiosurgery for Brain Metastases.” Anticancer Res. 2016 Oct;36(10):5333-5337.
  6. Kishan AUGomez CL, Dawson NA, Dvorak R, Foster NM, Hoyt A, Hurvitz SA, Kusske A, Silver EL, Tseng C, McCloskey SA. “Increasing Appropriate BRCA1/2 Mutation Testing: The Role of Family History Documentation and Genetic Counseling in a Multidisciplinary Clinic.” Ann Surg Oncol. 2016 Sep 12.
  7. Qi XS, Wang JP, Gomez CL, Shao W, Xu X, King C, Low DA, Steinberg M, Kupelian P. “Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy.” Radiother Oncol. 2016 Aug 29. pii: S0167-8140(16)34255-4.
  8. Shaverdian N, Veruttipong D, Wang J, Kupelian P, Steinberg M, Lee P. “Pretreatment Anemia Portends Poor Survival and Nonlocal Disease Progression in Patients with Stage I Non-Small Cell Lung Cancer Treated with Stereotactic Body Radiation Therapy.” J Thorac Oncol. 2016 Aug;11(8):1319-25.
  9. Kishan AU, Duchesne G, Wang PC, Rwigema JM, Saigal C, Rettig M, Steinberg ML, King CR. “Does Specialty Bias Trump Evidence in the Management of High-risk Prostate Cancer?” Am J Clin Oncol. 2016 Aug 24.
  10. Kishan AU, Shaikh T, Wang PC, Reiter RE, Said J, Raghavan G, Nickols NG, Aronson WJ, Sadeghi A, Kamrava M, Demanes DJ, Steinberg ML, Horwitz EM, Kupelian PA, King CR. “Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis.” Eur Urol. 2016 Jul 21. pii: S0302-2838(16)30398-0.
  11. Kishan AU, Wang PC, Sharif J, Kupelian PA, Steinberg ML, McCloskey SA. “Clinical Indicators of Psychosocial Distress Predict for Acute Radiation Induced Fatigue in Patients Receiving Whole Breast Radiotherapy: A Prospective Analysis of Patient-Reported Outcomes.” Int J Radiat Oncol Biol Phys. 2016 Jul 1;95(3):946-55.
  12. Kishan AU, Lee P. “Having Your Cake and Eating It Too: Combining SBRT and Multi-agent Chemotherapy in Locally Advanced Pancreatic Cancer.” Cureus. 2016 Jul 13;8(7):e686.
  13. Hegde JV, Collins SP, Fuller DB, King CR, Demanes DJ, Wang PC, Kupelian PA, Steinberg ML, Kamrava M. “A Pooled Analysis of Biochemical Failure in Intermediate-risk Prostate Cancer Following Definitive Stereotactic Body Radiotherapy (SBRT) or High-Dose-Rate Brachytherapy (HDR-B) Monotherapy.” Am J Clin Oncol. 2016 Jun 17.
  14. Pennington JD, Park SJ, Lee PP, Demanes DJ. “Comment on “Medical use of all high activity sources should be eliminated for security concerns” [Med. Phys. 42, 6773-6775 (2015)].” Med Phys. 2016 Jul;43(7):4459.
  15. Gou S, Lee P, Hu P, Rwigema JC, Sheng K. “Feasibility of automated 3-dimensional magnetic resonance imaging pancreas segmentation.” Advances in Radiation Oncology. 1;3:182-193.
  16. Shaverdian N, Tenn S, Veruttipong D, Wang J, Hegde J, Lee C, Cao M, Agazaryan N, Steinberg M, Kupelian P, Lee P“The significance of PTV dose coverage on cancer control outcomes in early stage non-small cell lung cancer patients treated with highly ablative stereotactic body radiation therapy.” Br J Radiol. 2016 Mar;89(1059):20150963.
  17. Kishan AU, Lee P. “MRI-Guided Radiotherapy: Opening our Eyes to the Future.” Integrative Cancer Science and Therapeutics. 2016 3: DOI: 10.15761/ICST.1000181.
  18. Kishan AU, McCloskey SA.  “Postmastectomy radiation therapy after neoadjuvant chemotherapy: review and interpretation of available data.” Ther Adv Med Oncol. 2016 Jan;8(1):85-97.
  19. Rwigema JC, Lee P.  “Is staging mediastinoscopy necessary before stereotactic body radiotherapy for inoperable early stage lung cancer?” J Thorac Dis. 2015 Dec;7(12):E612-4.
  20. Shaverdian N, Veruttipong D, Wang J, Schaue D, Kupelian P, Lee P. “Pretreatment Immune Parameters Predict for Overall Survival and Toxicity in Early-Stage Non-Small-Cell Lung Cancer Patients Treated With Stereotactic Body Radiation Therapy.” Clin Lung Cancer. 2016 Jan;17(1):39-46.
  21. Merna C, Rwigema JC, Cao M, Wang PC, Kishan AU, Michailian A, Lamb J, Sheng K, Agazaryan N, Low DA, Kupelian P, Steinberg ML, Lee P. “A treatment planning comparison between modulated tri-cobalt-60 teletherapy and linear accelerator-based stereotactic body radiotherapy for central early-stage non-small cell lung cancer.” Med Dosim. 2016 Spring;41(1):87-91.
  22. Yang Y, Cao M, Kaprealian T, Sheng K, Gao Y, Han F, Gomez C, Santhanam A, Tenn S, Agazaryan N, Low DA, Hu P. “Accuracy of UTE-MRI-based patient setup for brain cancer radiation therapy.” Med Phys.2016 Jan;43(1):262.


  1. Kishan AU, Wang PC, Upadhyaya SK, Hauswald H, Nickols NG, Kamrava M, Sadeghi A, Kupelian PA, Steinberg ML, Demanes DJ, Prionas ND, Buyyounouski MK, King CR.  “SBRT and HDR Produce Lower PSA Nadirs and Different PSA Decay Patterns Than Conventionally Fractionated IMRT in Patients With Low or Intermediate Risk Prostate Cancer.” Pract Radiat Oncol. 2016 Jul-Aug;6(4):268-75.
  2. Kishan AU, Lee EW, McWilliams J, Lu D, Genshaft S, Motamedi K, Demanes DJ, Park S, Hagio M, Wang PC, Kamrava M.  “Brachyablation: Preliminary Outcomes and Toxicity of a Joint Interventional Radiology and Radiation Oncology Technique For Achieving Local Control in Challenging Cases.” Journal of Contemporary Brachytherapy. 2015 Oct;7(5):327-35.
  3. Kishan AU, Steinberg ML, Kupelian PA, King CR. “The Challenges of Delivering SBRT Safely: In Regard to Bauman et al.” Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1162-3.
  4. Shaverdian N, Wang PC, Steinberg M, Lee P. “The patient’s perspective on stereotactic body radiation therapy (SBRT) vs. surgery for treatment of early stage non-small cell lung cancer (NSCLC).” Lung Cancer. 2015 Nov;90(2):230-3.
  5. Kang JJ, Steinberg ML, Kupelian P, Alexander S, King CR. “Whole Versus Partial Bladder Radiation: Use of an Image-guided Hypofractionated IMRT Bladder-preservation Protocol.” Am J Clin Oncol. 2015 Nov 3.
  6. Kishan AU, Cameron RB, Wang PC, Alexander S, Qi SX, Low DA, Kupelian PA, Steinberg ML, Lee JM, Selch MT, Lee P. “Tomotherapy improves local control and changes failure patterns in locally advanced malignant pleural mesothelioma.” Pract Radiat Oncol. 2015 Nov-Dec;5(6):366-73.
  7. Kamrava M, Kishan AU, Margolis DJ, Huang J, Dorey F, Lieu P, Kupelian PA, Marks L. “Multiparametric MRI for prostate cancer improves Gleason score assessment in favorable risk prostate cancer.” Pract Radiat Oncol. 2015 Nov-Dec;5(6):411-6.
  8. Kishan AU, Park SJ, King CR, Roberts K, Kupelian PA, Steinberg ML, Kamrava M. “Dosimetric benefits of hemigland stereotactic body radiotherapy for prostate cancer: implications for focal therapy.” Br J Radiol. 2015 Oct 28:20150658
  9. Kishan AU, Cao M, Mikaeilian AG, Low DA, Kupelian PA, Steinberg ML, Kamrava M. “Dosimetric Feasibility of MRI-guided Tri-Cobalt-60 Preoperative Intensity Modulated Radiation Therapy for Soft Tissue Sarcomas of the Extremity.” Pract Radiat Oncol. 2015 Sep-Oct;5(5):350-6.
  10. Kishan AU, Cao M, Wang PC, Mikaeilian AG, Tenn S, Rwigema JC, Sheng K, Low DA, Kupelian PA, Steinberg ML, Lee P. “Feasibility of magnetic resonance imaging-guided liver stereotactic body radiation therapy: A comparison between modulated tri-cobalt-60 teletherapy and linear accelerator-based intensity modulated radiation therapy.” Pract Radiat Oncol. 2015 Sep-Oct;5(5):330-7.
  11. Kang JJ, Reiter RE, Kummer N, DeKernion J, Steinberg ML, King CR. “Wrong to be Right: Margin Laterality is an Independent Predictor of Biochemical Failure After Radical Prostatectomy.” Am J Clin Oncol. 2015 Jul 31.
  12. Gomez CL, Xu X, Qi XS, Wang PC, Kupelian P, Steinberg M, King CR. “Dosimetric parameters predict short-term quality-of-life outcomes for patients receiving stereotactic body radiation therapy for prostate cancer.” Pract Radiat Oncol. 2015 Jul-Aug;5(4):257-62.
  13. Pennington JD, Park SJ, Abgaryan N, Banerjee R, Lee PP, Loh C, Lee E, Demanes DJ, Kamrava M. “Dosimetric comparison of brachyablation and stereotactic ablative body radiotherapy in the treatment of liver metastasis.” Brachytherapy. 2015 Jul-Aug;14(4):537-42.
  14. Kishan AU, Lamb JM, Jani S, Kang JJ, Steinberg ML, King CR. “Pelvic Nodal Dosing With Registration to the Prostate: Implications for High-Risk Prostate Cancer Patients Receiving SBRT.” Int J Radiat Oncol Biol Phys. 2015 Mar 15;91(4):832–839.
  15. Mesko S, Park SJ, Kishan AU, Demanes DJ, Kamrava M. “A sector-based dosimetric analysis of dose heterogeneity in high-dose-rate prostate brachytherapy.” Brachytherapy. 2015 Mar-Apr;14(2):173-8.
  16. Kishan AU, Kupelian PA. “Late rectal toxicity after low-dose-rate brachytherapy: Incidence, predictors, and management of side effects.” Brachytherapy. 2015. March – April;14(2):148-159.
  17. Rwigema JC, Nguyen D, Heron DE, Chen AM, Lee P, Vargo JA, Low DA, Huq S, Steinberg ML, Kupelian P, Sheng Ke. “4π Noncoplanar Stereotactic Body Radiation Therapy for Head and Neck Cancers – Potential to Improve Tumor Control and Late Toxicity.” Int J Radiat Oncol Biol Phys. 2015 Feb 1;91(2):401-9.
  18. Kamrava M, Hegde JV, Abgaryan N, Chang E, Le JD, Wang J, Kupelian P, Marks LS. “Does the Addition of Targeted Prostate Biopsies to Standard Systemic Biopsies Impact Treatment Management for Radiation Oncologists?” BJU Int. Apr;117(4):584-91.


  1. Kang JJ, Reiter RE, Steinberg ML, King CR. “Ultrasensitive Prostate Specific Antigen after Prostatectomy Reliably Identifies Patients Requiring Postoperative Radiotherapy.” J Urol. 2015 May;193(5):1532-8.
  2. Nguyen D, Rwigema JC, Yu V, Sheng Ke. “Feasibility of extreme dose escalation for Glioblastoma Multiforme using 4π radiotherapy.” Radiat Oncol. 2014 Nov 7;9(1):239.
  3. Rwigema JC, King C, Wang P-C, Kamrava M, Kupelian P, Steinberg ML, Lee P. “Stereotactic Body Radiation Therapy for Abdominal and Pelvic Oligometastases: Dosimetric Targets for Safe and Effective Local Control.” Pract Radiat Oncol. 2014 Oct 24. pii: S1879-8500(14)00249-5.
  4. Kishan AU, Cui J, Wang PC, Daly ME, Purdy JA, Chen AM. “Quantification of gross tumour volume changes between simulation and first day of radiotherapy for patients with locally advanced malignancies of the lung and head/neck.” J Med Imaging Radiat Oncol. 2014 Oct;58(5):618-24.
  5. Kishan AU, Wang P, Sheng K, Yu V, Ruan D, Cao M, Tenn S, Low DA, Lee P. “Correlation of Clinical and Dosimetric Parameters with Radiographic Lung Injury Following Stereotactic Body.” Technol Cancer Res Treat. 2014 Sep 26.
  6. Gomez C, Shah C, McCloskey S, Foster N, Vicini F. “The role of radiation therapy after nipple-sparing mastectomy.” Ann Surg Oncol. 2014 Jul;21(7):2237-44.
  7. Rwigema JC, Chen AM, Wang PC, Lee JM, Garon E, Lee P. “Incidental mediastinal dose does not explain low mediastinal node recurrence rates in patients with early-stage NSCLC treated with stereotactic body radiotherapy.” Clin Lung Cancer. 2014 Jul;15(4):287-93.
  8. Yu V, Kishan AU, Cao M, Low D, Lee P, Ruan D. “Dose impact in radiographic lung injury following lung SBRT: Statistical analysis and geometric interpretation.” Med Phys. 2014 Mar;41(3):031701.


  1. Lee P, Kang JJ. “In reply to Sharma et al.” Int J Radiat Oncol Biol Phys. 2013 Nov 15;87(4):631-2.
  2. Yang F, Nickols NG, Li BC, Szablowski JO, Hamilton SR, Meier JL, Wang CM, Dervan PB. “Animal toxicity of hairpin pyrrole-imidazole polyamides varies with the turn unit.” J Med Chem. 2013 Sep 26;56(18):7449-57.
  3. Kamrava M, Rwigema JC, Chung M, Banerjee R, Wang J, Steinberg M, Demanes DJ. “Predictors of distant metastasis after combined HDR brachytherapy and external beam radiation for prostate cancer.” J Contemp Brachytherapy. 2013 Sep;5(3):127-33.
  4. Sollier E, Go DE, Che J, Gossett DR, O’Byrne S, Weaver WM, Kummer N, Rettig M, Goldman J, Nickols N, McCloskey S, Kulkarni RP, Di Carlo D. “Size-selective collection of circulating tumor cells using Vortex technology.” Lab Chip. 2014 Jan 7;14(1):63-77.
  5. Lee P, Eppinga W, Lagerwaard F, Cloughesy T, Slotman B, Nghiemphu PL, Wang PC, Kupelian P, Agazaryan N, Demarco J, Selch MT, Steinberg M, Kang JJ. “Evaluation of high ipsilateral subventricular zone radiation therapy dose in glioblastoma: a pooled analysis.” Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):609-15.
  6. Mehta NH, Kamrava M, Wang PC, Steinberg M, Demanes J. “Prostate-specific antigen bounce after high-dose-rate monotherapy for prostate cancer.”  Int J Radiat Oncol Biol Phys. 2013 Jul 15;86(4):729-33.
  7. Nickols NG, Szablowski JO, Hargrove AE, Li BC, Raskatov JA, Dervan PB. “Activity of a Py-Im polyamide targeted to the estrogen response element.” Mol Cancer Ther. 2013 May;12(5):675-84.
  8. Yang F, Nickols NG, Li BC, Marinov GK, Said JW, Dervan PB. “Antitumor activity of a pyrrole-imidazole polyamide. Proc Natl Acad Sci U S A. 2013 Jan 29;110(5):1863-8.
  9. Singhvi M, Lee P. “Illustrative cases of false positive biopsies after stereotactic body radiation therapy for lung cancer based on abnormal FDG-PET-CT imaging.” BMJ Case Rep. 2013 Jan 22;2013.


  1. Lin CS, Selch MT, Lee SP, Wu JK, Xiao F, Hong DS, Chen CH, Hussain A, Lee PP, De Salles AA. “Accelerator-based stereotactic radiosurgery for brainstem metastases.” Neurosurgery. 2012 Apr;70(4):953-8
  2. Raskatov JA, Nickols NG, Hargrove AE, Marinov GK, Wold B, Dervan PB. “Gene expression changes in a tumor xenograft by a pyrrole-imidazole polyamide.” Proc Natl Acad Sci U S A. 2012 Oct 2;109(40):16041-5.
  3. Synold TW, Xi B, Wu J, Yen Y, Li BC, Yang F, Phillips JW, Nickols NG, Dervan PB. “Single-dose pharmacokinetic and toxicity analysis of pyrrole-imidazole polyamides in mice.” Cancer Chemother Pharmacol. 2012 Oct;70(4):617-25.
  4. Mehta N, King CR, Agazaryan N, Steinberg M, Hua A, Lee P. “Stereotactic Body Radiation Therapy (SBRT) and Three-Dimensional Conformal Radiotherapy (#D-CRT) for Stage I Non-Small Cell Lung Cancer (NSCLC): A Pooled Analysis of Biological Equivalent Dose (BED) and Local Control.” Practical Radiation Oncology. 2012. Oct;2(4):288-295.